{"id":58365,"date":"2025-01-09T10:45:41","date_gmt":"2025-01-09T09:45:41","guid":{"rendered":"https:\/\/ticker-noticiasep.microcontenidos.com\/NoticiaRSS.vbhtml?user=FRND562DLP&cod=20250109104541"},"modified":"2025-01-09T10:45:41","modified_gmt":"2025-01-09T09:45:41","slug":"salud-grunenthal-appoints-prof-dr-uli-brodl-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/webciudadana.net\/?p=58365","title":{"rendered":"Salud: Gr\u00fcnenthal appoints Prof. Dr. Uli Br\u00f6dl as Chief Scientific Officer"},"content":{"rendered":"\n
<\/div>\n

(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n

\nNEWS AKTUELL \/\/ Aachen, Germany, 09 January 2025 – Gr\u00fcnenthal announced today that Prof. Dr. Uli Br\u00f6dl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.<\/p>\n

Uli Br\u00f6dl has more than 15 years of industry experience. He joins Gr\u00fcnenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim’s Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Br\u00f6dl led Boehringer Ingelheim’s Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.<\/p>\n

Uli Br\u00f6dl graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich.<\/p>\n

\u00abThe unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Gr\u00fcnenthal,\u00bb says Uli Br\u00f6dl. \u00abI look forward to joining the team and further driving Gr\u00fcnenthal’s innovation pipeline.\u00bb<\/p>\n

\u00abWith Uli, we have been able to attract an excellent leader,\u00bb says Gabriel Baertschi, CEO of Gr\u00fcnenthal. \u00abHis extensive experience in R&D and commercial functions combined with Uli’s drive to bring innovative medicines to patients will help us propel our vision of a world free of pain.\u00bb <\/p>\n

\nAbout Gr\u00fcnenthal<\/p>\n

\nGr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.<\/p>\n

Gr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Gr\u00fcnenthal employed around 4,400 people and achieved revenues of \u20ac1.8 billion.<\/p>\n

More information: https:\/\/www.grunenthal.com<\/p>\n

\nFollow us on:<\/p>\n

\nLinkedIn: Grunenthal Group<\/p>\n

\nInstagram: grunenthal<\/p>\n

\nFor further information, please contact:<\/p>\n

\nFlorian Dieckmann, Head Global Corporate Affairs & Communication<\/p>\n

\nTel.: +49 241 569-2555<\/p>\n

\nFlorian.Dieckmann@grunenthal.com<\/p>\n","protected":false},"excerpt":{"rendered":"

(Informaci\u00f3n remitida por la empresa firmante) NEWS AKTUELL \/\/ Aachen, Germany, 09 January 2025 – Gr\u00fcnenthal announced today that Prof. Dr. Uli Br\u00f6dl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Br\u00f6dl has more than 15 years of industry experience. He joins […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-58365","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/58365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58365"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/58365\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}